Processa Pharmaceuticals (PCSA) Interest & Investment Income (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Interest & Investment Income came in at $13859.0 in Q1 2026, up 10.12% YoY from $12585.0 in Q1 2025, and up 10.12% on a QoQ basis from $12585.0 in Q1 2025.
Processa Pharmaceuticals (PCSA) Interest & Investment Income (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 14 years of Interest & Investment Income data on file, last reported at $13859.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 10.12% year-over-year to $13859.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $304726.0 (up 46.75% YoY) and the FY2025 annual result came in at $109491.0, down 45.55% from the prior year.
- Interest & Investment Income climbed to $13859.0 in Q1 2026, from $12585.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $238132.0 in Q4 2024 to a low of -$83217.0 in Q1 2024.
- A 5-year average of $42990.0 and a median of $36708.0 in 2022 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 1972.73% in 2022, down 67.96% in 2022.
- Tracing PCSA's Interest & Investment Income over 5 years: stood at $55530.0 in 2022, then gained by 16.19% to $64519.0 in 2023, then surged by 269.09% to $238132.0 in 2024, then sank by 94.72% to $12585.0 in 2025, then grew by 10.12% to $13859.0 in 2026.
- The last three Interest & Investment Income figures came in at $13859.0 (Q1 2026), $12585.0 (Q1 2025), and $238132.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | -2,003.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,859.00 |
| Mar 31, 2025 | 12,585.00 |
| Dec 31, 2024 | 238,132.00 |
| Sep 30, 2024 | 40,150.00 |
| Mar 31, 2024 | -83,217.00 |
| Dec 31, 2023 | 64,519.00 |
| Sep 30, 2023 | 85,661.00 |
| Dec 31, 2022 | 55,530.00 |
| Sep 30, 2022 | 36,708.00 |
| Jun 30, 2022 | 7,380.00 |
| Mar 31, 2022 | 1,583.00 |
| Dec 31, 2021 | 3,826.00 |
| Sep 30, 2021 | 1,771.00 |
| Jun 30, 2021 | 1,814.00 |
| Mar 31, 2021 | 4,940.00 |
| Dec 31, 2020 | 2,315.00 |
| Sep 30, 2020 | 12.00 |
| Jun 30, 2020 | 18.00 |
| Mar 31, 2020 | 829.00 |
| Dec 31, 2019 | 662.00 |